The Hindu Business Line : Ranbaxy drug gets FDA nod

NEW DELHI: Ranbaxy Laboratories Ltd has received final approval from the US Food and Drug Administration (FDA) to manufacture and market gabapentin capsules used for certain nerve-related disorders.

Ranbaxy's formulations are found to have the same therapeutic effect as Pfizer's Neurontin Capsules. The total sales for oral gabapentin were $2.2 billion, while sales of gabapentin capsules totalled $1.2 billion. Gabapentin is indicated for the management of postherpetic neuralgia in adults and can also be used in the treatment of partial seizures.

Mr Venkat Krishnan, Vice-President, Ranbaxy Inc, USA, "This product demonstrates Ranbaxy's capabilities to formulate multiple oral product dosage forms."

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Marico arm buys toilet soap brand in Bangladesh

GAIL draws up tight schedule for Ratnagiri LNG terminal closure

Ranbaxy drug gets FDA nod

IVRCL bags NHAI orders

Now, small-time manufacturing units join outsourcing party

Award for Biocon CMD

Ennore Port's coal terminal hits legal speed-breaker

Canbank AMC finalises terms to buy GIC Mutual

Yanmar picks up 12 pc stake in International Tractors for Rs 200 cr

Pilkington plans to set up subsidiary in India

Dentsu India ties up with Pakistan's Evernew

Swiss mint firm enters domestic bullion market
Ties up with Clarity Gold, to set up minting facility at Jaipur

Emaar, Samsung sign $876-m deal

`Sight for Kids' programme

BPCL hopeful of rise in gross refining margins

`Delphi's Indian operations will not be affected'

Hind Paper offers incentives to dealers